Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Microbot Medical ( (MBOT) ) just unveiled an announcement.
Microbot Medical Inc. has announced a significant milestone in its ACCESS-PVI clinical trial, successfully enrolling and following up with half of the participants for its LIBERTY® Endovascular Robotic Surgical System. The company is on track to complete the trial by the fourth quarter of 2024, with plans to submit for FDA approval by the end of the year. The system, praised for its ease of use and potential to revolutionize endovascular procedures, could democratize interventional surgeries through its innovative remote operation capabilities.
See more data about MBOT stock on TipRanks’ Stock Analysis page.
